Is Multaq heading for trouble? Steve Nissen thinks so!

Steve Nissen provided the following comment to CardioExchange about Multaq:

I have significant concerns about the safety, efficacy and tolerability of dronedarone.  Although liver toxicity was not anticipated, other safety issues have been apparent even prior to launch. The increased risk of death in heart failure patients represented a particularly concerning finding in pre-approval studies.  The drug is substantially less efficacious compared with amiodarone and the GI tolerability is poor. Despite these warning signs, the drug has been aggressively promoted, often through industry-sponsored CME offered by professional medical societies. Over-promotion of a risky drug during its initial launch period has been a historically important harbinger of serious safety concerns. Dronedarone may be headed for trouble.

via cardiobrief.org

Posted via email from Jack's posterous